Sign up to save your podcasts
Or
Share NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM at ESMO — Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
View all episodes
By NEJM Group
4.4
120120 ratings
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
139 Listeners
Medicine and Science from The BMJ
42 Listeners
NEJM Journal Watch Podcasts: Clinical Conversations
59 Listeners
NEJM This Week
322 Listeners
JACC This Week
170 Listeners
JAMA Clinical Reviews
502 Listeners
Mayo Clinic Talks
282 Listeners
JAMA Medical News
89 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
135 Listeners
Leadership Conversations
6 Listeners
Core IM | Internal Medicine Podcast
1,111 Listeners
Curbside Consults
90 Listeners
Annals On Call Podcast
195 Listeners
The Clinical Problem Solvers
518 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
350 Listeners
The Curious Clinicians
366 Listeners
Infectious Disease Puscast
85 Listeners
NEJM AI Grand Rounds
52 Listeners
Intention to Treat
32 Listeners
Not Otherwise Specified
45 Listeners